The relationship between thyroid and breast diseases has been documented, but the clinical significance of Graves' disease and breast cancer is unclear. We present a young patient with a history of Graves' disease who developed a multicentric infiltrating ductal carcinoma of the breast several months after discontinuing her treatment with propylthiouracil. Early-onset breast cancer in women wit...

A 67 year old man presented with a well differentiated follicular carcinoma of the thyroid 17 years after he had been given radioactive iodine for Graves' disease. As this was insufficient to cure him he had continued to take propylthiouracil regularly. The tumour, which had completely replaced the thyroid, was apparently maintaining thyrotoxicosis. The implications of this management are discu...

A 3 year old child with Graves' disease and mitral valve prolapse became neutropenic on carbimazole therapy. She was switched to propylthiouracil but the neutropenia recurred. She was treated with radioiodine but required two doses of 113 MBq and then 198 MBq five months later before becoming hypothyroid. The mitral valve prolapse resolved when she was euthyroid on thyroxine replacement. Antith...

Taste sensitivity to the bitter compound 6-n-propylthiouracil (PROP) is a genetic trait present in 70% of the population, and it is sensitive even at low concentrations of the compound (FOX, 1932). PROP tasters have a higher density of fungiform papillae and tend to perceive a wide variety of compounds, such as caffeine, sucrose, pepper, and fat with greater intensity (TEPPER, 2008; TEPPER; CHR...

The side effects of propylthiouracil, including cytopenia and vasculitis, are well established.  We present an interesting case in which cytopenia and cutaneous vasculopathy occurred concomitantly in a critically ill patient.  The patient was initially treated for suspected infection until dermatologic and rheumatologic workup revealed ANCA-positivity and vasculopathy on histopathology, most co...

In order to compare the effect of propylthiouracil (PTU) of Iran Hormone Co. and that of Dr. Herbrand KG, Germany, 28 patients with toxic goiter entered this study. Each patient received 200 mg PTU daily for the first 4 weeks and 50 mg daily thereafter. 17 patients received PTU from Iran Hormone (group 1) and 111 took PTU from Germany (group 2). T4, T3 and TSH by RIA and resine T3, uptake were ...